ENDP · Endo International PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $451.67M | $546.85M | $515.27M | - | $541.69M | $569.11M | $652.26M | - | $772.03M |
| Cost of Revenue | - | $230.29M | $233.85M | $232.74M | - | $261.23M | $263.79M | $273.21M | - | $286.07M |
| Gross Profit | - | $221.38M | $313.00M | $282.52M | - | $280.46M | $305.33M | $379.04M | - | $485.96M |
| R&D | - | $31.58M | $28.04M | $27.70M | - | $25.62M | $29.79M | $29.74M | - | $25.62M |
| SG&A | - | $138.77M | $137.73M | $150.79M | - | $192.22M | $180.83M | $227.16M | - | $246.86M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | $77.87M | - | - | - | $106.31M | - | - |
| Operating Income | - | ($16.89M) | $34.29M | $2.95M | - | ($707.59M) | ($1.87B) | ($67.11M) | - | ($47.74M) |
| Interest Expense | - | $10.0K | $120.0K | $109.0K | - | $74.75M | $139.78M | $134.95M | - | $142.96M |
| Income Tax | - | $11.04M | $10.28M | $5.77M | - | $10.68M | $7.15M | ($1.81M) | - | $1.55M |
| Net Income | - | ($28.48M) | $23.44M | ($3.28M) | - | ($722.17M) | ($1.89B) | ($71.97M) | - | ($77.21M) |
| EPS - Basic | - | ($0.12) | $0.10 | ($0.01) | - | ($3.07) | ($8.02) | ($0.31) | - | ($0.33) |
| EPS - Diluted | - | ($0.12) | $0.10 | ($0.01) | - | ($3.07) | ($8.02) | ($0.31) | - | ($0.33) |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $777.92M | $823.30M | $865.92M | $903.61M | $1.02B | $1.05B | $1.19B | $1.41B | $1.51B | $1.57B |
| Accounts Receivable | $386.92M | $387.49M | $447.88M | $459.36M | $493.99M | $423.46M | $491.49M | $473.30M | $592.02M | $533.83M |
| Inventory | $246.02M | $273.83M | $274.54M | $285.28M | $274.50M | $288.91M | $287.76M | $283.83M | $283.55M | $297.30M |
| Accounts Payable | $94.73M | $90.91M | $87.93M | $96.75M | $109.03M | $85.00M | $90.64M | $101.01M | $123.13M | $111.05M |
| Current Assets | $1.67B | $1.75B | $1.86B | $1.93B | $2.08B | $2.05B | $2.20B | $2.49B | $2.71B | $2.75B |
| Total Assets | $5.14B | $5.26B | $5.42B | $5.57B | $5.76B | $6.01B | $6.36B | $8.45B | $8.77B | $9.25B |
| Current Liabilities | $538.79M | $564.63M | $564.88M | $606.64M | $689.63M | $543.05M | $1.18B | $1.38B | $1.63B | $1.55B |
| Long-term Debt | $8.15B | $7.39B | $7.54B | $7.69B | $0 | $0 | $8.04B | $8.04B | $8.05B | $8.05B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | ($6.60B) | ($4.16B) | ($4.13B) | ($4.15B) | ($4.16B) | ($3.93B) | ($3.20B) | ($1.31B) | ($1.24B) | ($690.32M) |
| Retained Earnings | ($15.35B) | ($12.91B) | ($12.88B) | ($12.91B) | ($12.90B) | ($12.66B) | ($11.94B) | ($10.05B) | ($9.98B) | ($9.42B) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | $62.10M | - | - | - | $201.32M | - | - |
| Investing Cash Flow | - | - | - | ($21.36M) | - | - | - | ($48.84M) | - | - |
| Financing Cash Flow | - | - | - | ($144.72M) | - | - | - | ($189.20M) | - | - |
| CapEx | - | - | - | $31.28M | - | - | - | $23.02M | - | - |
| Free Cash Flow | - | - | - | $30.82M | - | - | - | $178.29M | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 49.0% | 57.2% | 54.8% | - | 51.8% | 53.6% | 58.1% | - | 62.9% |
| Operating margin | - | -3.7% | 6.3% | 0.6% | - | -130.6% | -329.2% | -10.3% | - | -6.2% |
| EBITDA margin | - | - | - | 15.7% | - | - | - | 6.0% | - | - |
| Net margin | - | -6.3% | 4.3% | -0.6% | - | -133.3% | -331.3% | -11.0% | - | -10.0% |
| Free cash flow margin | - | - | - | 6.0% | - | - | - | 27.3% | - | - |
| FCF / Net income | - | - | - | -9.40 | - | - | - | -2.48 | - | - |
| R&D / Revenue | - | 7.0% | 5.1% | 5.4% | - | 4.7% | 5.2% | 4.6% | - | 3.3% |
| SG&A / Revenue | - | 30.7% | 25.2% | 29.3% | - | 35.5% | 31.8% | 34.8% | - | 32.0% |
| Effective tax rate | - | - | 30.5% | 231.5% | - | - | - | - | - | - |
| Return on assets | - | -0.5% | 0.4% | -0.1% | - | -12.0% | -29.6% | -0.9% | - | -0.8% |
| Return on equity | - | 0.7% | -0.6% | 0.1% | - | 18.4% | 59.0% | 5.5% | - | 11.2% |
| Return on invested capital | - | -0.4% | 0.7% | 0.0% | - | - | -30.6% | -0.8% | - | -0.5% |
| Liquidity | ||||||||||
| Current ratio | 3.10 | 3.11 | 3.30 | 3.18 | 3.01 | 3.78 | 1.86 | 1.81 | 1.67 | 1.77 |
| Quick ratio | 2.64 | 2.62 | 2.81 | 2.71 | 2.61 | 3.25 | 1.62 | 1.61 | 1.49 | 1.58 |
| Cash ratio | 1.44 | 1.46 | 1.53 | 1.49 | 1.48 | 1.94 | 1.01 | 1.03 | 0.92 | 1.01 |
| Leverage | ||||||||||
| Debt / Equity | -1.23 | -1.78 | -1.83 | -1.85 | 0.00 | 0.00 | -2.51 | -6.13 | -6.47 | -11.66 |
| Debt / Assets | 1.59 | 1.41 | 1.39 | 1.38 | 0.00 | 0.00 | 1.26 | 0.95 | 0.92 | 0.87 |
| Debt / EBITDA | - | - | - | 95.17 | - | - | - | 205.13 | - | - |
| Interest coverage | - | -1689.4x | 285.8x | 27.1x | - | -9.5x | -13.4x | -0.5x | - | -0.3x |
| Equity multiplier | -0.78 | -1.26 | -1.31 | -1.34 | -1.38 | -1.53 | -1.99 | -6.44 | -7.05 | -13.39 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | 0.09 | 0.10 | 0.09 | - | 0.09 | 0.09 | 0.08 | - | 0.08 |
| Inventory turnover | - | 0.84 | 0.85 | 0.82 | - | 0.90 | 0.92 | 0.96 | - | 0.96 |
| Days sales outstanding | - | 313d | 299d | 325d | - | 285d | 315d | 265d | - | 252d |
| Days inventory outstanding | - | 434d | 428d | 447d | - | 404d | 398d | 379d | - | 379d |
| Days payable outstanding | - | 144d | 137d | 152d | - | 119d | 125d | 135d | - | 142d |
| Cash conversion cycle | - | 603d | 590d | 621d | - | 570d | 588d | 509d | - | 490d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -16.6% | -3.9% | -21.0% | - | -29.8% | -20.3% | -9.1% | - | 21.6% |
| Revenue CAGR (3y) | - | -10.7% | -7.3% | -14.4% | - | -9.4% | -6.7% | -3.3% | - | 1.2% |
| Revenue CAGR (5y) | - | -9.5% | -5.2% | -6.0% | - | -7.2% | -8.3% | -8.9% | - | -2.7% |
| Gross profit growth (YoY) | - | -21.1% | 2.5% | -25.5% | - | -42.3% | -22.8% | -8.1% | - | 69.5% |
| Operating income growth (YoY) | - | 97.6% | - | - | - | -1382.1% | - | - | - | 26.3% |
| Net income growth (YoY) | - | 96.1% | - | 95.4% | - | -835.4% | -12064.0% | - | - | -1.7% |
| EPS growth (YoY) | - | 96.1% | - | 96.8% | - | -830.3% | -11357.1% | - | - | 0.0% |
| EPS CAGR (3y) | - | - | 26.0% | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | -82.7% | - | - | - | -21.5% | - | - |
| FCF CAGR (5y) | - | - | - | 5.2% | - | - | - | 4.9% | - | - |
| Book value growth (YoY) | -58.5% | -6.0% | -29.1% | -216.8% | -234.6% | -468.6% | -418.3% | -118.9% | -92.0% | 11.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Business segments
$2.01B totalBranded Pharmaceuticals Segment$859.09M · 42.7%
Generic Pharmaceuticals Segment$650.35M · 32.3%
Sterile Injectables Segment$429.56M · 21.4%
International Pharmaceuticals Segment$72.52M · 3.6%
Product / service
$2.15B totalSpecialty Products$645.66M · 30.1%
Xiaflex$475.01M · 22.1%
Other Sterile Injectables$236.47M · 11.0%
Established Products$213.43M · 9.9%
PERCOCET$106.38M · 5.0%
Adrenalin$99.91M · 4.7%
SUPPRELINLA$96.85M · 4.5%
Vasostrict$93.18M · 4.3%
Other Specialty Products$73.80M · 3.4%
Other Established Products$64.59M · 3.0%
Lidoderm$42.46M · 2.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Endo International plc against the 5 most active filers in the same SIC group.